Paul Marks to Head Search Committee For National Cancer Institute Director
WASHINGTON--HHS Secretary Donna Shalala has appointed Paul Marks, president, Memorial Sloan-Kettering Cancer Institute, to chair the search committee for a director of the National Cancer Institute, to replace Dr. Samuel Broder, who now plans to leave in March instead of April as originally announced.
WASHINGTON--HHS Secretary Donna Shalala has appointed Paul Marks,president, Memorial Sloan-Kettering Cancer Institute, to chairthe search committee for a director of the National Cancer Institute,to replace Dr. Samuel Broder, who now plans to leave in Marchinstead of April as originally announced.
The 14-member committee (twice as large as the one convened tofind a replacement for Vincent DeVita) is expected to make itsrecommendations to the White House by March 15.
Other committee members are Frances Visco, JD, National BreastCancer Coalition; Karen Antman, Columbia University; FernandoCabanillas, M.D. Anderson; Anthony Fauci, National Institute ofAllergy and Infectious Diseases; Harold Freeman, chairman, President'sCancer Panel; Maxine Singer, Carnegie Institute; and Eli Glatsteinand Joseph Goldstein, University of Texas Southwestern MedicalCenter.
Also, Kenneth Olden, National Institute of Environmental HealthSciences; Shirley Tilghman, Howard Hughes Medical Institute; ChristopherWalsh, Dana-Farber; Samuel Wells, Washington University; and CharlesWilson, University of California, San Francisco.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
